34th Annual CFS™ Chemotherapy Foundation Satellite Symposium®
34th Annual CFS™ Chemotherapy Foundation Satellite Symposium®Thursday, November 10, 2016
10:30 AM - 12:00 PM
CME-Certified Concurrent Symposium - Live Taping: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future Direction
New York Marriott Marquis
New York, NY 10036
Room: Julliard Complex (5th Floor)
Registration is complimentary, but seating is limited. Please register here.
This edition of Medical Crossfire®, filmed in conjunction with the 34th Annual CFS™ Chemotherapy Foundation Symposium
®, has been designed to provide a dynamic discussion of the expanding role of poly ADP-ribose polymerase (PARP) inhibitors in the care of patients with ovarian cancer. With one PARP inhibitor already approved for ovarian cancer (in patients with BRCA-mutated disease) by the Food and Drug Administration and several others in phase III testing in various indications, the time is, now, for clinicians to get up-to-date on the rationale for the use of PARP inhibitors in this lethal disease, as well as the established and emerging clinical data supporting their use.
Our activity chair, Maurie Markman, MD, and our expert faculty will each present brief overviews of key topics related to PARP inhibitors in ovarian cancer, including their rationale, resistance mechanisms to PARP inhibition, their use in different treatment strategies, and the role of genetic testing to identify those patients to be treated with these agents. Each presentation will be followed by an engaging panel discussion and Q&A session led by Dr. Markman.
This educational activity is directed toward all attendees of the 34th Annual CFS™ Chemotherapy Foundation Symposium
®, including physicians, nurse practitioners, nurses, and physician assistants with an interest in treating patients with ovarian cancer. Pharmacists, researchers, and other health care providers interested in the treatment of ovarian cancer are also be invited to attend.
Upon completion of this activity, participants will be better prepared to:
Describe the rationale for the application of PARP inhibitors in ovarian cancer
Outline the resistance mechanisms to PARP inhibitors in ovarian cancer
Discuss the evolving treatment strategies for PARP inhibition in the treatment of ovarian cancer, including the role in monotherapy, combination therapy, and maintenance therapy
Assess the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease
Maurie Markman, MD
President, Medicine and Science
Cancer Treatment Centers of America
Michael J. Birrer, MD, PhD
Professor, Harvard Medical School
Director, Gynecologic Medical Oncology
Massachusetts General Hospital Leader, DF/HCC Gynecologic Cancers Program
Michael A. Bookman, MD
Director, Gynecologic Oncology Research
US Oncology Research and Arizona Oncology
Mark E. Robson, MD
Attending Physician, Clinical Genetics and Breast Medicine Services
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center UC College of Medicine
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Aknowledgement of Commercial Support
This activity is supported by an educational grant from Clovis Oncology Inc., Foundation Medicine, and Tesaro Inc.
Photos from the 34th Annual CFS™ Chemotherapy Foundation Satellite Symposium®